Phenytoin, Methotrexate, and Trimethoprim as Folic Acid Antagonists
Phenytoin, methotrexate (MTX), and trimethoprim are all folic acid antagonists that cause folate deficiency through distinct mechanisms: MTX and trimethoprim directly inhibit dihydrofolate reductase (the enzyme that converts dietary folate to its active tetrahydrofolate form), while phenytoin likely impairs folate absorption and increases hepatic metabolism.
Mechanisms of Folate Depletion
Methotrexate (MTX)
MTX is a direct and potent dihydrofolate reductase (DHFR) inhibitor 1. By blocking this enzyme, MTX prevents the conversion of dihydrofolate to tetrahydrofolate, which is essential for DNA synthesis, repair, and cellular replication 1. This mechanism underlies both its therapeutic effects (targeting rapidly dividing cells) and its toxicity profile.
Key toxicities from MTX-induced folate deficiency include:
- Myelosuppression (most common cause of MTX-related fatalities) 2
- Hepatotoxicity 2
- Gastrointestinal effects (nausea, stomatitis, anorexia) 2
- Megaloblastic anemia 3
Trimethoprim
Trimethoprim also inhibits DHFR, though with weaker potency than MTX 4. It competitively inhibits intestinal folate transport at the membrane level 4. A randomized controlled trial demonstrated that 400 mg daily trimethoprim for just 7 days significantly lowered serum folate levels in healthy participants (mean decrease of 1.95 nmol/L vs. 0.21 nmol/L increase in placebo, p=0.040) 5.
The FDA drug label explicitly warns: "Hematological changes indicative of folic acid deficiency may occur in elderly patients or in patients with preexisting folic acid deficiency or kidney failure" 6. Risk is particularly elevated when trimethoprim is combined with MTX, as noted in the MTX drug label: "Trimethoprim/sulfamethoxazole has been reported rarely to increase bone marrow suppression in patients receiving methotrexate, probably by decreased tubular secretion and/or an additive antifolate effect" 1.
Phenytoin
Phenytoin's mechanism differs from the direct DHFR inhibition seen with MTX and trimethoprim. While the exact mechanism remains uncertain, phenytoin likely causes folate deficiency through 7, 3:
- Reduced intestinal folate absorption
- Prevention of folate release from tissue stores
- Increased hepatic folate metabolism
- Altered plasma protein binding
Critical clinical consideration: The phenytoin-folate interaction is bidirectional. When phenytoin therapy begins without folate supplementation, serum folate decreases 7. However, folic acid supplementation in folate-deficient patients already on phenytoin changes phenytoin pharmacokinetics, typically lowering serum phenytoin concentrations and potentially causing seizure breakthrough 7. The FDA label for MTX specifically lists phenytoin as a drug that may displace MTX from serum albumin, potentially increasing MTX toxicity 1.
Clinical Management: Folate Supplementation
For Methotrexate Therapy
Folic acid supplementation is mandatory for all patients on MTX 2, 8. The evidence is strongest here:
- Dosing: 1-5 mg daily, given every day EXCEPT the day of MTX administration 2
- Benefits: A Cochrane review demonstrated that ≤7 mg/week folic acid with MTX significantly reduced:
Important: Folic acid does NOT reduce MTX efficacy 8, 9. Use folic acid (not folinic acid) for routine supplementation—folinic acid is more expensive with no proven advantage and should be reserved for MTX toxicity/overdose 8, 1.
For Trimethoprim Therapy
The FDA label recommends folate supplementation for high-risk patients: those with impaired renal/hepatic function, elderly patients, chronic alcoholics, patients on anticonvulsants, or those with malabsorption 6. Folinic acid therapy reverses hematologic changes from folate deficiency 6.
For Phenytoin Therapy
Folic acid supplementation should be initiated when phenytoin therapy commences 7. This prevents folate depletion, allows phenytoin to reach true steady-state concentrations sooner, and avoids the pharmacokinetic perturbations that occur when folate is added later 7. However, adding folate to established phenytoin therapy requires careful monitoring as it may lower phenytoin levels and precipitate seizures.
Critical Drug Interactions
The combination of MTX with trimethoprim or phenytoin requires heightened vigilance:
- MTX + Trimethoprim: Listed as a drug interaction in MTX labeling 2, 1. Monitor closely for bone marrow suppression.
- MTX + Phenytoin: Phenytoin may displace MTX from albumin, increasing free MTX levels and toxicity 1. The MTX label specifically warns about this interaction.
- MTX + NSAIDs/Sulfonamides: These also reduce tubular secretion of MTX and may enhance toxicity 1.
Risk Factors for Folate Deficiency-Related Toxicity
Patients at highest risk when taking these medications include 2, 6:
- Advanced age
- Renal insufficiency (85% of MTX is renally excreted) 2
- Absence of folate supplementation
- Chronic alcoholism
- Malabsorption syndromes
- Concurrent use of other folate antagonists
- Hypoalbuminemia
Monitor these patients more frequently with CBC, liver function tests, and renal function 8.